{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-096647","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.427777+00:00","generated_at":"2026-05-31T06:23:56.346972+00:00","sec_items":["2.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Collegium closes $525M Ironshore acquisition; adds Jornay PM, boosts 2024 outlook","bullets":["Ironshore acquired for $525M cash plus potential $25M milestone based on Jornay PM 2025 net revenue.","Jornay PM (ADHD) expected >$100M net revenue in 2024; prescriptions grew 32% YoY in H1 2024.","2024 guidance updated: product revenue $620-635M, adjusted EBITDA $395-405M, reflecting four months of Ironshore.","Financed with $200M cash and $325M draw on new $646M term loan; interest rate reduced 300 bps.","Establishes presence in neurology/ADHD; Jornay PM poised as leading growth driver; patents to 2032."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-096647","json":"https://secwatch.observer/filing/0001104659-24-096647.json","markdown":"https://secwatch.observer/filing/0001104659-24-096647.md","text":"https://secwatch.observer/filing/0001104659-24-096647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924096647/0001104659-24-096647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924096647/tm2423139d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:23:56.346972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8915333e827007c5be81a27bd81c9d59030092c2","claim":"COLLEGIUM PHARMACEUTICAL, INC completed an acquisition involving Ironshore Therapeutics Inc. for approximately $525 million in cash (closed 2024-09-03).","evidence_excerpt":"The aggregate consideration paid by the Company at the Closing pursuant to the Merger Agreement was approximately $525 million in cash (subject to customary adjustments for net working capital, indebtedness, cash, and transaction expenses), with one potential future commercial milestone payment of $25 million.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924096647/0001104659-24-096647-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Ironshore Therapeutics Inc."},{"label":"Consideration","value":"approximately $525 million in cash"},{"label":"Closing","value":"2024-09-03"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}